Introducing NMDP, formerly known as the National Marrow Donor Program and Be The Match. Our name has changed but our mission has not: We save lives through cell therapy. Learn More

Autologous (your own cells) blood or marrow transplant (BMT) followed by HST-NEETs, to treat human immunodeficiency virus (HIV)-related lymphoma


15 and older

Phase 2

13 Locations


Clinical Trial Goal

To find out if autologous BMT followed by HST-NEETs is safe and works well to treat HIV-related lymphoma

You may be able to join this trial if you:

  • Are 15 years old or older
  • Have HIV and are being treated with antiretroviral therapies (ART)
  • Have lymphoma that has relapsed or is refractory. Some examples include:
    • Burkitt lymphoma
    • Diffuse large B-cell lymhpoma (DLBCL)
    • Hodgkin lymphoma
    • Immunoblastic lymphoma
    • Plasmablastic lymhpoma
    • Primary effusion lymphoma
  • Do not have lymphoma in your brain or spinal cord
  • Have not an autologous (your own cells) or allogeneic (cells from a donor) blood or marrow transplant (BMT)
  • Have not had CAR T-cell therapy
  • Agree to have other standard tests done to see if you can be in the clinical trial

Trial Details

Carmustine, cytarabine, etoposide and melphalan are chemotherapy (chemo) drugs that block the growth of cancer cells. 
HST-NEETS are HIV-1 specific T-cells that target and attack HIV. HST-NEETS are made using your own blood-forming cells, which are then modified in a lab.  

First, you’ll have apheresis, a process to collect, separate and save your blood-forming cells.

Before transplant you'll get chemo with 4 standard drugs:
  • Carmustine
  • Cytarabine
  • Etoposide
  • Melphalan

On transplant day, your own blood-forming cells are given back to you through an intravenous (IV) infusion.

After transplant, you’ll get:
  • HST-NEETs – Given as an IV infusion 1 time

You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.

The Food and Drug Administration (FDA) has not yet approved HST-NEETs after autologous BMT to treat HIV-related lymphoma. 


Nicole Ritzau,

Christine Borchert, 301-251-1161,


City of Hope National Medical CenterRecruiting

Duarte, California
Matthew Mei,


Washington, District of Columbia
Anne Renteria,

Miami Cancer InstituteNot yet recruiting

Miami, Florida
Marco Ruiz Andia,

H. Lee Moffitt Cancer CenterRecruiting

Tampa, Florida
Alex Lazaryan,


Atlanta, Georgia
Lawrence Morris, 404-851-6908,

University of IllinoisRecruiting

Chicago, Illinois

  • Paul Rubinstein

Johns Hopkins UniversityRecruiting

Baltimore, Maryland
Rich Ambinder,

CornellNot yet recruiting

New York, New York
Anna A Alperovich,

Icahn School of Medicine at Mount SinaiRecruiting

New York, New York
Uroosa Ibrahim,

Memorial Sloan Kettering (MSKCC)Recruiting

New York, New York
Parastoo Dahi,

University of PennsylvaniaRecruiting

Philadelphia, Pennsylvania
Stefan Barta,

Baylor College of MedicineRecruiting

Houston, Texas
George Carrum,

MD AndersonRecruiting

Houston, Texas
Uday Popat, record

NCT04975698. First posted on 7/23/21

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator